Skip to main content

Table 1 Patient characteristics at time of accrual.

From: A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases

Parameter
Total Number of Patients 35
Age 59 ± 8 years
Gender  
   Male 24 (69%)
   Female 11 (31%)
Site of Primary Tumor  
   Colon 22 (63%)
   Rectosigmoid 7 (20%)
   Rectum 6 (17%)
Previous Treatment for Primary Tumor  
   Chemotherapy 11 (31%)
   Radiotherapy 6 (17%)
Initial Staging  
   Stage I 1 (3%)
   Stage II 4 (11%)
   Stage III 9 (26%)
   Stage IV (ie: synchronous liver metastases) 21 (60%)
Metachronous liver metastases 14 (40%)
   Median disease-free interval (range) 24 mo (4–61 mo)
Mean Number of Liver Lesions 2 ± 3
   Solitary metastasis 21 (60%)
   > 1 metastases 14 (40%)
Size of Largest Liver Lesion 5.0 ± 2.6 cm
   ≤ 5 cm 21 (60%)
   > 5 cm 14 (40%)
Carcinoembryogenic Antigen 31 ± 41 ng/mL